These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 24186934)

  • 1. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.
    Yabluchanskiy A; Ma Y; Iyer RP; Hall ME; Lindsey ML
    Physiology (Bethesda); 2013 Nov; 28(6):391-403. PubMed ID: 24186934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMP-2: is too low as bad as too high in the cardiovascular system?
    Hardy E; Hardy-Sosa A; Fernandez-Patron C
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1332-H1340. PubMed ID: 30118342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction.
    Deleon-Pennell KY; Altara R; Yabluchanskiy A; Modesti A; Lindsey ML
    IUBMB Life; 2015 Aug; 67(8):611-8. PubMed ID: 26269290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas' cardiomyopathy.
    Medeiros NI; Gomes JAS; Correa-Oliveira R
    Parasite Immunol; 2017 Aug; 39(8):. PubMed ID: 28543409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade.
    Vandooren J; Van den Steen PE; Opdenakker G
    Crit Rev Biochem Mol Biol; 2013; 48(3):222-72. PubMed ID: 23547785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adiponectin attenuates profibrotic extracellular matrix remodeling following cardiac injury by up-regulating matrix metalloproteinase 9 expression in mice.
    Jenke A; Schur R; Röger C; Karadeniz Z; Grüger M; Holzhauser L; Savvatis K; Poller W; Schultheiss HP; Landmesser U; Skurk C
    Physiol Rep; 2017 Dec; 5(24):. PubMed ID: 29263115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
    Lizotte-Waniewski M; Brew K; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S; Lijnen HR
    Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases (MMPs) in health and disease: an overview.
    Malemud CJ
    Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies.
    St-Pierre Y; Van Themsche C; Estève PO
    Curr Drug Targets Inflamm Allergy; 2003 Sep; 2(3):206-15. PubMed ID: 14561155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Inflammation Alters MMP-2 and MMP-9 Gelatinase Expression Associated with the Severity of Nifedipine-Induced Gingival Overgrowth: a Rat Model Study.
    Li WL; Wu CH; Yang J; Tang M; Chen LJ; Zhao SL
    Inflammation; 2015 Aug; 38(4):1517-28. PubMed ID: 25652432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase-9 in lung remodeling.
    Atkinson JJ; Senior RM
    Am J Respir Cell Mol Biol; 2003 Jan; 28(1):12-24. PubMed ID: 12495928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches.
    Ziviello F; Conte S; Cimmino G; Sasso FC; Trimarco B; Cirillo P
    Curr Vasc Pharmacol; 2017; 15(3):197-206. PubMed ID: 28034366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases.
    Xue C; Sowden MP; Berk BC
    Arterioscler Thromb Vasc Biol; 2018 May; 38(5):986-993. PubMed ID: 29599134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYLD-mediated signaling and diseases.
    Mathis BJ; Lai Y; Qu C; Janicki JS; Cui T
    Curr Drug Targets; 2015; 16(4):284-94. PubMed ID: 25342597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
    Liu J; Khalil RA
    Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiology in perspective: cell migration and the regenerative process.
    Sieck G
    Physiology (Bethesda); 2013 Nov; 28(6):368-9. PubMed ID: 24186931
    [No Abstract]   [Full Text] [Related]  

  • 19. Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution.
    Iyer RP; de Castro Brás LE; Patterson NL; Bhowmick M; Flynn ER; Asher M; Cannon PL; Deleon-Pennell KY; Fields GB; Lindsey ML
    J Mol Cell Cardiol; 2016 Nov; 100():109-117. PubMed ID: 27746126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial matrix metalloproteinase-2: inside out and upside down.
    DeCoux A; Lindsey ML; Villarreal F; Garcia RA; Schulz R
    J Mol Cell Cardiol; 2014 Dec; 77():64-72. PubMed ID: 25261607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.